Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart home tech could help lung patients breathe easier at home

NCT ID NCT06601790

Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests a smart home system for people with interstitial lung disease, a condition that makes breathing difficult. Participants use home devices to track their health and do exercises, with the goal of improving symptoms and reducing hospital visits. The study compares those who start the system right away to those who wait three months, measuring changes in breathing, mood, and overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Smart Homespital system (behavioral intervention with home monitoring and exercise)
What this could lead to
If effective, this system could help people with interstitial lung disease manage their condition from home, potentially reducing hospital stays and improving quality of life.
What could go wrong
This is a small, early-stage trial with 83 participants, so results may not apply to everyone. The system relies on patients using the equipment correctly, and it may not work for those with severe limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

83 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients diagnosed with COPD who meet the following pulmonary function test results: 1. Pre FEV1 \< 80% \*\*or\*\* 2. Pre FVC \< 80% \*\*or\*\* 3. DLCO \< 60% Exclusion Criteria: 1. Patients who do not agree to participate in the study. 2. Patients who fail to use the medical device equipment. 3. Patients where tracking during the study period is expected to be impossible. 4. Patients who have difficulty communicating verbally. 5. Patients who are bedridden or unable to exercise at all due to severe cardiorespiratory dysfunction. 6. Patients receiving hospital-centered rehabilitation treatment during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease

Contacts and locations

Locations

  • Division of Pulmonary and Critical Care Medicine

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.